News
Advances in myeloma treatments, diagnostics have specialists ‘talking about cure’
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies...
An exciting treatment for the multiple myeloma community
A leading international consultant haematologist in the treatment of multiple myeloma, Professor Saad Z. Usmani, Chief of Plasma Cell Disorders...
Scientists stumble on promising agent for incurable cancer
Kiwi researchers have stumbled upon what could be a promising agent against an incurable blood cancer. Based on just-published findings, Otago...
FDA Commissioner Voices Concerns About CAR T-Cell Therapy Payment
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, expressed concern in October over the price of chimeric antigen receptor...
New study sheds light on how CAR T cell therapy works
Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly...
Newsletter: October 2018
Greetings. Spring is in the air and the end of the year is fast approaching. Save the Date The final patient seminar and end of year function...
FDA Approves NGS-Based Test for Patients With ALL or MM
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal...
Bisphosphonates for Patients Diagnosed With Multiple Myeloma
Clinical Question Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures,...
Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of...
Update on diagnosis, risk‐stratification and management
Multiple myeloma accounts for approximately 10% of hematologic malignancies. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy...
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma
Researchers at The University of Alabama at Birmingham are recruiting for a phase 2 clinical trial designed to offer an innovative treatment...
Patient Seminar: From 45 South – The Otago Myeloma Research Trust
Presented by Dr Ian Morison on 1 August, 2018 Watch the video below